Mineralys Therapeutics, Inc. MLYS 深 滬
已收盤 12-12 16:00:00 美东时间
36.90
+0.850
+2.36%
華盛通- 最 高39.15
- 今 開36.45
- 成交量 212.47万股
- 最 低 35.87
- 昨 收 36.05
- 總市值 24.46亿
- 52周最高 47.65
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 8.241
- 委 比 79.89%
- 總股本 6629.52万
- 歷史最高 47.65
- 量 比 1.57
- 振 幅 9.10%
- 歷史最低 5.85
- 每 手 1
- 風險率 12.26%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mineralys Therapeutics' Phase 3 Launch-HTN Trial Of Lorundrostat Featured In JAMA's Inaugural "Research Of The Year Roundup"
– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful of 2025 by JAMA
12-13 00:02
期权扫描 | 狂飙！台积电期权放量7倍，看涨期权占比近9成；PLTR多张Call单大涨逾200%
狂飙！台积电期权放量7倍，看涨期权占比近9成；获美国海军大单！PLTR多张Call单大涨逾200%；优步一Put单涨超240%，遭市场押注续跌>>
12-11 11:28
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
Mineralys Therapeutics Q3 EPS $(0.52) Beats $(0.65) Estimate
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.65) by 19.38 percent. This is a 53.98 percent increase over losses of $(1.13) per share
11-11 05:08
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Reported Friday, Mineralys Therapeutics Showcases Broad Clinical Potential of Lorundrostat Across Cardio-Renal-Metabolic Diseases
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week –– Pivotal Phase 3 Launch-HTN trial featured in the "Best of JAMA and NEJM" session -
11-10 17:42
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
HC Wainwright & Co. Maintains Buy on Mineralys Therapeutics, Raises Price Target to $52
HC Wainwright & Co. analyst Matthew Caufield maintains Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and raises the price target from $42 to $52.
10-30 19:54
Mineralys Therapeutics Presents Phase 2 Explore-CKD Trial Of Lorundrostat At ASN Kidney Week 2025
~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be presented~~ Phase 3 data of the Launch-HTN Trial of lorundrostat to
10-21 20:08
